| NCT05397470 | Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH) | TERMINATED | PHASE3 | 2022-06-16 | 2024-11-19 | 2024-11-19 |
| NCT05169580 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir | RECRUITING | PHASE1 | 2021-12-13 | 2025-12 | 2025-09 |
| NCT05002231 | Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets | COMPLETED | PHASE1 | 2021-08-19 | 2021-10-22 | 2021-10-05 |
| NCT04586985 | Safety, Tolerability and Pharmacokinetics of FTX-6058 | COMPLETED | PHASE1 | 2020-10-26 | 2022-11-15 | 2022-11-15 |
| NCT04511819 | Losmapimod Safety and Efficacy in COVID-19 | TERMINATED | PHASE3 | 2020-08-28 | 2021-03-31 | 2021-03-31 |
| NCT04264442 | Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE) | TERMINATED | PHASE2 | 2020-02-13 | 2024-11-07 | 2024-11-07 |
| NCT04004000 | Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension | TERMINATED | PHASE2 | 2019-08-23 | 2024-10-31 | 2024-10-31 |
| NCT04003974 | Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) | COMPLETED | PHASE2 | 2019-08-09 | 2021-01-28 | 2021-01-28 |